Last update 30 Mar 2025

Dupilumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Dupilumab (Genetical Recombination), Dupilumab (genetical recombination) (JAN), Dupilumab (USAN)
+ [10]
Target
Action
inhibitors
Mechanism
IL-4Rα inhibitors(Interleukin-4 receptor subunit alpha inhibitors)
Originator Organization
Active Organization
Drug Highest PhaseApproved
First Approval Date
United States (28 Mar 2017),
RegulationOrphan Drug (United States), Priority Review (China), Overseas New Drugs Urgently Needed in Clinical Settings (China), Priority Review (Australia), Priority Review (United States), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D10354Dupilumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pulmonary Disease, Chronic Obstructive
European Union
03 Jul 2024
Pulmonary Disease, Chronic Obstructive
Iceland
03 Jul 2024
Pulmonary Disease, Chronic Obstructive
Liechtenstein
03 Jul 2024
Pulmonary Disease, Chronic Obstructive
Norway
03 Jul 2024
Chronic Urticaria
Japan
09 Feb 2024
Chronic Urticaria
Japan
09 Feb 2024
Eosinophilic Esophagitis
Canada
06 Feb 2018
prurigo nodularis
Australia
24 Jan 2018
Asthma
European Union
26 Sep 2017
Asthma
Iceland
26 Sep 2017
Asthma
Liechtenstein
26 Sep 2017
Asthma
Norway
26 Sep 2017
Chronic rhinosinusitis with nasal polyps
European Union
26 Sep 2017
Chronic rhinosinusitis with nasal polyps
Iceland
26 Sep 2017
Chronic rhinosinusitis with nasal polyps
Liechtenstein
26 Sep 2017
Chronic rhinosinusitis with nasal polyps
Norway
26 Sep 2017
Dermatitis, Atopic
United States
28 Mar 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pemphigoid, BullousNDA/BLA
United States
18 Feb 2025
Pemphigoid, BullousNDA/BLA
United States
18 Feb 2025
Eosinophilic DuodenitisPhase 3
United States
03 May 2023
Eosinophilic DuodenitisPhase 3
United States
03 May 2023
Eosinophilic DuodenitisPhase 3
Japan
03 May 2023
Eosinophilic DuodenitisPhase 3
Japan
03 May 2023
Eosinophilic DuodenitisPhase 3
Australia
03 May 2023
Eosinophilic DuodenitisPhase 3
Australia
03 May 2023
Eosinophilic DuodenitisPhase 3
Canada
03 May 2023
Eosinophilic DuodenitisPhase 3
Canada
03 May 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
71
(Dupilumab 300 mg q2w)
zpxlucordu(lwytylrwsc) = wjwwjrkjdj hrofdbbcme (foteqarryw, 3.91)
-
25 Mar 2025
placebo
(Placebo)
xxlpbtultv(uofvykdhrb) = esynzqjthk bungleohic (sblefdpxjs, 2.26)
Phase 3
935
Inhaled Corticosteroid
oqmvcmhkmz = sadqzwpyhj lsuewgllpq (nvyfphcdvd, bkpzjqgrqz - dfacevupnq)
-
25 Mar 2025
Phase 4
Asthma
Add-on
blood eosinophil count
-
Dupilumab 300 mg
egpmypxffo(hykgrpcgfo) = jwnuqqfoja durqnjrwsr (ufoxotjkhe )
Positive
01 Mar 2025
Placebo
egpmypxffo(hykgrpcgfo) = odjmotjvui durqnjrwsr (ufoxotjkhe )
Phase 3
Persistent asthma
Maintenance
blood eosinophils | fractional exhaled nitric oxide
414
Dupilumab 200 mg
orgootgakd(qxfspqvssp) = ckmafcwxpj ixowgrtugm (rkcwbbxzbe, 0.23 - 0.39)
Positive
23 Feb 2025
Placebo
-
Phase 3
Add-on
-
Dupilumab 300 mg
axkcgzaxjk(vjvucqacxl) = pfqjukuelu tkagxtlyly (xdiguedvpw )
Positive
01 Jan 2025
Placebo
axkcgzaxjk(vjvucqacxl) = vlgystrxmi tkagxtlyly (xdiguedvpw )
Phase 2/3
-
ihgrcxirgd(xzrazzcakb) = Significantly more patients receiving dupilumab versus placebo with FAs and numerically more patients without FAs achieved an IGA score of 0/1 (p = 0.0007 and p = 0.06). qxncxiaitq (imcbxjxyze )
Positive
01 Dec 2024
Placebo
Phase 4
202
Placebo
uugnpmbzcp(bliryhxsgq) = yhnzsapapy peanihktyx (sftxxaqrlr, 0.077)
-
26 Nov 2024
Not Applicable
-
nskxoozkvk(hcebwmjkrf) = One patient with high-titer ADAs developed serum sickness bbazeuejpj (urvvedpcaz )
-
11 Nov 2024
Phase 3
Persistent asthma
Add-on
blood eosinophils
174
dkdafnxfwg(kajwwecjto) = The incidence of treatment emergent adverse events was similar with dupilumab and placebo hypvgtacww (plcgvtirhf )
Positive
01 Nov 2024
Phase 3
151
kqcalwwqwn(gjyrxpuxai) = odnvbyeazo cupogsyogj (bjedcqzltp )
Positive
24 Oct 2024
Placebo
kqcalwwqwn(gjyrxpuxai) = znzskmzqkg cupogsyogj (bjedcqzltp )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free